Ke Yi
Ke Yi
Homepage

About me

~ •

Ke Yi

Guangzhou, P. R. China

Tel: +86-135-4796-0573

mail: keyi26@outlook.com

1. About

Powerful theoretical knowledge and skills in CRISPR/Cas gene editing with system construction

Senior experience in cancer immunotherapy, including messenger RNA synthesis and delivery, T cell engineering, and adoptive T cell therapy

Extensive experience in synthesis and optimization of liposomes, polymeric nanoparticles, and magnetic nanoparticles

2. Education

Sichuan University

Chengdu, P. R. China

2015.09 ~ 2019.06

B.S in Biological Science

Sun Yat-sen University

Guangzhou, P. R. China

2019.06 ~ 2024.06

Ph.D in Basic Medicine (Molecular Medicine)

  • Liposomes for combination cancer therapy of CRISPR/Cas systems and tyrosine kinase inhibitors
  • Adoptive cell immunotherapy based on liposome-engineered T cell for solid tumor treatment

3. Skills

Experimental skills

Materials: Preparation of liposomes, polymeric nanoparticles, and magnetic nanoparticles

Molecular Biology: Construction of CRISPR/Cas systems, Synthesis of IVT mRNA, RT-qPCR, Western blot, ELISA

Cell Biology: Cell culture, Cell transfection, extraction and expansion of primary T cells, flow cytometry, fluorescence microscopy

In vivo drug administration: Intravenous, subcutaneous and intraperitoneal injections, gavage, and in situ implantation of biomaterials (nanofiber meshes, 3D-printed scaffolds, and hydrogels) on liver

Establishing Tumor-bearing mouse models： subcutaneous melanoma/prostate cancer/hepatic cell carcinoma (HCC) model, and orthotopic HCC Model

4. Honor

2023, National Scholarship for Ph.D. Students in China

2019 & 2021, 2nd-class Scholarship for Ph.D. Students at Sun Yat-sen University

5. Publication

(1). First Author and Co-first Author (†)

  1. Yi, K.†, Kong, H.†, Lao, Y.-H.†, Li, D., Mintz, R.L., Fang, T., Chen, G., Tao, Y., Li, M., Ding, J., 2023. Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy. Adv. Mater. e2300665. https://doi.org/10.1002/adma.
  2. Yi, K., Kong, H., Zheng, C., Zhuo, C., Jin, Y., Zhong, Q., Mintz, R.L., Ju, E., Wang, H., Lv, S., Lao, Y.-H., Tao, Y., Li, M., 2023. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy. Biomaterials 122349. https://doi.org/10.1016/j.biomaterials.2023.122349
  3. Wei, H.†, Yi, K.†, Li, F., Li, D., Yang, J., Shi, R., Jin, Y., Wang, H., Ding, J., Tao, Y., Li, M., n.d. Multimodal Tetrahedral DNA Nanoplatform for Surprisingly Rapid and Significant Treatment of Acute Liver Failure. Advanced Materials n/a, 2305826. https://doi.org/10.1002/adma.202305826
  4. Guan, Y.†, Yao, W.†, Yi, K.†, Zheng, C., Lv, S., Tao, Y., Hei, Z., Li, M., 2021. Nanotheranostics for the Management of Hepatic Ischemia-Reperfusion Injury. Small 17, 2007727. https://doi.org/10.1002/smll.202007727
  5. Kong, H.†, Ju, E.†, Yi, K.†, Xu, W., Lao, Y.-H., Cheng, D., Zhang, Q., Tao, Y., Li, M., Ding, J., 2021. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv. Sci. 8, 2102051. https://doi.org/10.1002/advs.202102051
  6. Li, F.†, Zhang, J.†, Yi, K.†, Wang, H., Wei, H., Chan, H.F., Tao, Y., Li, M., 2022. Delivery of Stem Cell Secretome for Therapeutic Applications. ACS applied bio materials 5, 2009–2030. https://doi.org/10.1021/acsabm.1c01312

（2）Co-author

  1. Tao, Y., Yi, K., Wang, H., Kim, H.-W., Li, K., Zhu, X., Li, M., 2022. CRISPR-Cas12a-regulated DNA adsorption and metallization on MXenes as enhanced enzyme mimics for sensitive colorimetric detection of hepatitis B virus DNA. J Colloid Interface Sci 613, 406–414. https://doi.org/10.1016/j.jcis.2022.01.038
  2. Tao, Y., Yi, K., Hu, H., Shao, D., Li, M., 2021. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing. Journal of Materials Chemistry. B Online ahead of print. https://doi.org/10.1039/d0tb01925a
  3. Dang, W., Yi, K., Ju, E., Jin, Y., Xu, Y., Wang, H., Chen, W.-C., Wang, K., Wang, Y., Tao, Y., Li, M., 2021b. 3D Printed Bioceramic Scaffolds as a Universal Therapeutic Platform for Synergistic Therapy of Osteosarcoma. ACS Applied Materials \& Interfaces 13, 18488–18499. https://doi.org/10.1021/acsami.1c00553
  4. Tao, Y., Yi, K., Wang, H., Li, K., Li, M., 2022b. Metal nanoclusters combined with CRISPR-Cas12a for hepatitis B virus DNA detection. Sensors and Actuators B-Chemical 361, 131711. https://doi.org/10.1016/j.snb.2022.131711
  5. Kong, H., Yi, K., Zheng, C., Lao, Y.-H., Zhou, H., Chan, H.F., Wang, H., Tao, Y., Li, M., 2022. Membrane-fusogenic biomimetic particles: a new bioengineering tool learned from nature. J. Mater. Chem. B 10, 6841–6858.https://doi.org/10.1039/D2TB00632D
  6. Dang, W., Jin, Y., Yi, K., Ju, E., Zhuo, C., Wei, H., Wen, X., Wang, Y., Li, M., Tao, Y., 2021a. Hemin particles-functionalized 3D printed scaffolds for combined photothermal and chemotherapy of osteosarcoma. Chem. Eng. J. 422, 129919. https://doi.org/10.1016/j.cej.2021.129919
  7. Jin, Y., Wang, H., Yi, K., Lv, S., Hu, H., Li, M., Tao, Y., 2021. Applications of Nanobiomaterials in the Therapy and Imaging of Acute Liver Failure. Nano-micro Lett. 13, 25. https://doi.org/10.1007/s40820-020-00550-x
  8. Tao, Y., Lao, Y.-H., Yi, K., Xu, Y., Wang, H., Shao, D., Wang, J., Li, M., 2021a. Noble metal-molybdenum disulfide nanohybrids as dual fluorometric and colorimetric sensor for hepatitis B virus DNA detection. Talanta 234, 122675. https://doi.org/10.1016/j.talanta.2021.122675
  9. Zheng, C., Zhong, Q., Yi, K., Kong, H., Cao, F., Zhuo, C., Xu, Y., Shi, R., Ju, E., Song, W., Tao, Y., Chen, X., Li, M., 2023b. Anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) for adoptive cell immunotherapy. Sci. Adv. 9, eadh2413. https://doi.org/10.1126/sciadv.adh2413
  10. Zhong, Q., Zheng, C., Yi, K., Mintz, R.L., Lv, S., Tao, Y., Li, M., 2023. Structural and componential design: new strategies regulating the behavior of lipid-based nanoparticles in vivo. Biomater. Sci. 11, 4774–4788. https://doi.org/10.1039/d3bm00387f
  11. Zhuo, C., Kong, H., Yi, K., Chi, C.-W., Zhang, J., Chen, R., Wang, H., Wu, C., Lao, Y.-H., Tao, Y., Li, M., 2023. Magnetic-Activated Nanosystem with Liver-Specific CRISPR Nonviral Vector to Achieve Spatiotemporal Liver Genome Editing as Hepatitis B Therapeutics. Adv. Funct. Mater. 33, 2210860. https://doi.org/10.1002/adfm.202210860
  12. Zheng, C., Zhong, Q., Song, W., Yi, K., Kong, H., Wang, H., Tao, Y., Li, M., Chen, X., 2023a. Membrane-Fusion-Mediated Multiplex Engineering of Tumor Cell Surface Glycans for Enhanced NK Cell Therapy. Adv. Mater. n/a, 2206989. https://doi.org/10.1002/adma.202206989
  13. Jin, Y., Zhang, J., Xu, Y., Yi, K., Li, F., Zhou, H., Wang, H., Chan, H.F., Lao, Y.-H., Lv, S., Tao, Y., Li, M., 2023. Stem cell-derived hepatocyte therapy using versatile biomimetic nanozyme incorporated nanofiber-reinforced decellularized extracellular matrix hydrogels for the treatment of acute liver failure. Bioactive Materials 28, 112–131. https://doi.org/10.1016/j.bioactmat.2023.05.001
  14. Qin, Y., Lao, Y.-H., Wang, H., Zhang, J., Yi, K., Chen, Z., Han, J., Song, W., Tao, Y., Li, M., 2021. Combatting Helicobacter pylori with oral nanomedicines. J. Mater. Chem. B 9, 9826–9838. https://doi.org/10.1039/d1tb02038b

6. Conference presentations

  1. Poster Presnetation: A LIGHTFUL Nanomedicine Overcomes EGFR-Mediated Drug Resistance for Enhanced Tyrosine-Kinase-Inhibitor-Based Hepatocellular Carcinoma Therapy. The 5th Annual Meeting of Chinese American Society of Nanomedicine and Nanobiotechnology. Guangzhou, China, 2023.

7. Patent

  1. Li M., Tao Y., Yi, K., Kong H., Package (Membrabane-fusogenic liposome-based transfection reagent), 202230741460.5, Chinese Appearance Patent, 2023, authorized.
  2. Li M., Tao Y., Yi, K., Zhuo C., Package (Magnetic nanoparticle-based transfection reagent), 202230740676.X, Chinese Appearance Patent, 2023, authorized.
  3. Li M., Tao Y., Yi, K., Zhuo C., Kong H., Package (liver-specific gene-editing plasmid), 202230741458.8., Chinese Appearance Patent, 2023, authorized.
  4. Li M., Tao Y., Yi, K., Kong H., Zheng C., Zhuo C., Synthesis and application of a gene-editing nanodrug to overcome drug-resistance of tumor, 2023106238489, Chinese Invention Patent, submitted.
  5. Li M., Kong H., Zheng C., Yi, K., Tao Y., Synthesis and application of an antifouling membrane-fusogenic nanovector, 2023106237787, Chinese Invention Patent, submitted.
  6. Li M., Tao Y., Kong H., Zhuo C., Yi, K., Zheng C., Zhong Q., Synthesis and application of a gene-editing nanovector, 202210130435.2, Chinese Invention Patent, submitted.
  7. Li M., Tao Y., Zhuo C., Kong H., Yi, K., Dang W., Synthesis and application of a liver-specific gene-editing nanovedrug, 202210094797.0, Chinese Invention Patent, submitted.

Table of Contents